Idiopathic pulmonary fibrosis (IPF) is a chronic and devastating disease of unknown etiology, characterized by irreversible morphological changes, ultimately leading to lung fibrosis and death. In recent years, significant progress has been achieved in understanding the pathogenesis of IPF. Moreover, we assisted to the conceptual change of the pathogenic hypothesis that currently considers IPF as a primarily fibrotic driven disease. However, despite the undeniable progress, the diagnosis of IPF remains still very complex requiring the presence of a team of experts to achieve the highest level of diagnostic confidence. The advent of antifibrotics has radically changed the treatment landscape of IPF and new promising drugs are currently under evaluation. Furthermore, a more extensive use of non-pharmacological treatments has also to be encouraged in all patients both to reduce symptoms and improve quality of life.

Evolution and treatment of idiopathic pulmonary fibrosis

Torrisi S. E.;Vancheri C.;
2020-01-01

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic and devastating disease of unknown etiology, characterized by irreversible morphological changes, ultimately leading to lung fibrosis and death. In recent years, significant progress has been achieved in understanding the pathogenesis of IPF. Moreover, we assisted to the conceptual change of the pathogenic hypothesis that currently considers IPF as a primarily fibrotic driven disease. However, despite the undeniable progress, the diagnosis of IPF remains still very complex requiring the presence of a team of experts to achieve the highest level of diagnostic confidence. The advent of antifibrotics has radically changed the treatment landscape of IPF and new promising drugs are currently under evaluation. Furthermore, a more extensive use of non-pharmacological treatments has also to be encouraged in all patients both to reduce symptoms and improve quality of life.
2020
Aged
Anti-Inflammatory Agents, Non-Steroidal
Antibodies
Connective Tissue Growth Factor
Drug Therapy, Combination
Humans
Idiopathic Pulmonary Fibrosis
Indoles
Integrins
Leukotriene Antagonists
Lung Transplantation
Microbiota
Middle Aged
Multimorbidity
Phosphodiesterase Inhibitors
Phosphoric Diester Hydrolases
Protein Kinase Inhibitors
Pyridones
Serum Amyloid P-Component
File in questo prodotto:
File Dimensione Formato  
Evolution and treatment of idiopathic pulmonary fibrosis.pdf

solo gestori archivio

Tipologia: Versione Editoriale (PDF)
Dimensione 594.17 kB
Formato Adobe PDF
594.17 kB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/504401
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 15
social impact